Sang LX. Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”. World J Clin Cases 2021; 9(20): 5752-5753 [PMID: 34307635 DOI: 10.12998/wjcc.v9.i20.5752]
Corresponding Author of This Article
Li-Xuan Sang, PhD, Associate Professor, Department of Geriatrics, the First Affiliated Hospital, China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. sanglixuan2008@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Correction
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 16, 2021; 9(20): 5752-5753 Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5752
Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
Li-Xuan Sang
Li-Xuan Sang, Department of Geriatrics, The First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Sang LX solely contributed to this paper.
Conflict-of-interest statement: No conflicts of intererest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xuan Sang, PhD, Associate Professor, Department of Geriatrics, the First Affiliated Hospital, China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. sanglixuan2008@163.com
Received: January 11, 2021 Peer-review started: January 11, 2021 First decision: April 29, 2021 Revised: May 7, 2021 Accepted: May 24, 2021 Article in press: May 24, 2021 Published online: July 16, 2021 Processing time: 176 Days and 20.2 Hours
Abstract
Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. World J Clin Cases 2020; 8: 1361-1384. We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.
Core Tip: This manuscript is to further explain VSL#3 mentioned in it for probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases (World J Clin Cases 2020; 8: 1361-1384).
